Published online before print March 22, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Laboratory of Molecular Immunology, Rega Institute for Medical Research, Leuven, Belgium; and
Departments of Veterans Affairs and Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee
1 Correspondence: Laboratory of Molecular Immunology, Rega Institute, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. E-mail: jozef.vandamme{at}rega.kuleuven.ac.be
CC chemokine ligand 18 (CCL18) was originally discovered as pulmonary and activation-regulated chemokine (PARC), dendritic cell (DC)-chemokine 1 (DC-CK1), alternative macrophage activation-associated CC chemokine-1 (AMAC-1), and macrophage inflammatory protein-4 (MIP-4). CCL18 primarily targets lymphocytes and immature DC, although its agonistic receptor remains unknown so far. CCL18 is mainly expressed by a broad range of monocytes/macrophages and DC. A more profound understanding of the various activation programs and functional phenotypes of these producer cells might give a better insight in the proinflammatory versus anti-inflammatory role of this CC chemokine. It is interesting that CCL18 is constitutively present at high levels in human plasma and likely contributes to the physiological homing of lymphocytes and DC and to the generation of primary immune responses. Furthermore, enhanced CCL18 production has been demonstrated in several diseases, including various malignancies and inflammatory joint, lung, and skin diseases. The lack of a rodent counterpart for human CCL18 sets all hope on primate animal models to further elucidate the importance of CCL18 in vivo. This review will address these different aspects in more detail.
Key Words: dendritic cells • macrophages • chemotaxis • inflammatory • homing
This article has been cited by other articles:
 |
|
 |
|
  X. Li, T. Syrovets, S. Paskas, Y. Laumonnier, and T. Simmet Mature Dendritic Cells Express Functional Thrombin Receptors Triggering Chemotaxis and CCL18/Pulmonary and Activation-Regulated Chemokine Induction J. Immunol., July 15, 2008; 181(2): 1215 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lemarie, E. Bourdonnay, C. Morzadec, O. Fardel, and L. Vernhet Inorganic Arsenic Activates Reduced NADPH Oxidase in Human Primary Macrophages through a Rho Kinase/p38 Kinase Pathway J. Immunol., May 1, 2008; 180(9): 6010 - 6017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Shanmugam, J. L. Figarola, Y. Li, P. M. Swiderski, S. Rahbar, and R. Natarajan Proinflammatory Effects of Advanced Lipoxidation End Products in Monocytes Diabetes, April 1, 2008; 57(4): 879 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.O. Kraaijeveld, S.C.A. de Jager, W.J. de Jager, B.J. Prakken, S.R. McColl, I. Haspels, H. Putter, T.J.C. van Berkel, L. Nagelkerken, J.W. Jukema, et al. CC Chemokine Ligand-5 (CCL5/RANTES) and CC Chemokine Ligand-18 (CCL18/PARC) Are Specific Markers of Refractory Unstable Angina Pectoris and Are Transiently Raised During Severe Ischemic Symptoms Circulation, October 23, 2007; 116(17): 1931 - 1941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Muehlenbachs, M. Fried, J. Lachowitzer, T. K. Mutabingwa, and P. E. Duffy Genome-Wide Expression Analysis of Placental Malaria Reveals Features of Lymphoid Neogenesis during Chronic Infection J. Immunol., July 1, 2007; 179(1): 557 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wimmer, S. K. Khaldoyanidi, M. Judex, N. Serobyan, R. G. DiScipio, and I. U. Schraufstatter CCL18/PARC stimulates hematopoiesis in long-term bone marrow cultures indirectly through its effect on monocytes Blood, December 1, 2006; 108(12): 3722 - 3729. [Abstract] [Full Text] [PDF]
|
|
